Menu
Recruiting NCT05201131

Canadian Cohort of Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH).

Observational Urologic Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Rezum.
Who it may be relevant to
Registry conditions: Urologic Diseases. Basic parameters: from 18 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To document the clinical outcome of Rezūm therapy for BPH patient in Canadian cohort.

Interventions

  • Procedure Rezum
    Rezum

Primary outcome measures

  • Maximum flow rate (Q-max) [Time frame: Baseline]
  • Change of Maximum flow rate (Q-max) [Time frame: 1 month after surgery]
  • Change of Maximum flow rate (Q-max) [Time frame: 3 months after surgery]
  • Change of Maximum flow rate (Q-max) [Time frame: 6 months after surgery]
  • Change of Maximum flow rate (Q-max) [Time frame: 12 months after surgery]
  • Change of Maximum flow rate (Q-max) [Time frame: 24 months after surgery]
  • Change of Maximum flow rate (Q-max) [Time frame: 36 months after surgery]
  • Post-Void Residual (PVR) volume [Time frame: Baseline]
  • Change of Post-Void Residual (PVR) volume [Time frame: 1 month after surgery]
  • Change of Post-Void Residual (PVR) volume [Time frame: 3 months after surgery]

Eligibility criteria

Inclusion criteria

  • Male subjects of ≥ 18 years of age.
  • Primary diagnosis of Benign Prostate Hypertrophy (BPH).
  • Candidate for Rezūm therapy as per clinical decision of Investigator.
  • Willing and able to accurately complete the required questionnaires.
  • Willing and able to provide signed and dated informed consent

Exclusion criteria

  • Characteristics indicating a poor compliance with study protocol requirements.
  • Disease or other health condition that is not suitable for this study.
  • Unable or unwilling to provide signed informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Canada · 1 center
  • Dean Elterman — Toronto

Identifiers

NCT: NCT05201131 · Rezum in BPH CAN

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗